<div>
  <ul>
    <li>
      <p>
        Healx has entered an investment agreement with the Children's Tumor Foundation. The agreement, which will result in milestone-driven payments, builds on Healx and CTF's partnership established in 2020.
      </p>
    </li>
    <li>
      <p>
        The investments will help advance Healx&rsquo;s AI-driven neurofibromatosis program, including its lead candidate, HLX-1502, toward Phase II clinical trials in the coming months.&nbsp;&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://healx.ai/healx-to-receive-investment-from-childrens-tumor-foundation-to-advance-neurofibromatosis-type-1-treatments/">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

<div>
 <p>Healx and Children's Tumor Foundation (CTF) have formed an investment agreement, following their partnership in 2020. This arrangement will lead to milestone-based payments.</p>
 <p>Funds from this agreement will progress Healx’s AI-based neurofibromatosis program and its primary candidate, HLX-1502, into Phase II clinical trials soon.</p>
</div>

All Updates

Healx signs investment agreement with Children's Tumor Foundation to advance neurofibromatosis program to Phase II clinical trials

Healx collaborates with Ono Therapeutics to identify drug indications